素保护功能,改善氧化应激和脂质过氧化在老鼠慢性功能衰竭
Ningning Xu, Weinan Han, Guoping Yun
1Department of Pharmacy, Zhangjiakou City First Hospital, Zhangjiakou, China. lu_lu.shi@stu.ahu.edu.cn.
Iranian journal of kidney diseases
|June 20, 2023
概括
中发现的一种化合物阿利在患有慢性病 (CKD) 的老鼠中保护功能方面表现有前途. 它通过向ROS/MAPK/NF-κB通路来减少氧化应激和脂质过氧化,这表明它有可能作为治疗脏疾病的治疗剂.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性病 (CKD) 是一种严重的健康问题,其特点是逐渐丧失功能.
- 氧化应激和脂质过氧化在CKD的发病和进展中起着至关重要的作用.
- 识别可以减轻这些病理过程的治疗剂对于治疗脏疾病至关重要.
研究的目的:
- 在CKD的老鼠模型中研究艾利对功能的保护作用.
- 阐明氨酸在CKD中影响氧化应激和脂质过氧化的潜在机制.
- 评估艾利在改善损伤方面的剂量依赖性疗效.
主要方法:
- 60只大鼠被分配到模拟操作,CKD模型和不同剂量的氨酸剂量组.
- 通过测量血清肌素 (Scr),血液尿素 (BUN) 和24小时尿蛋白来评估功能.
- 脏氧化应激标志物 (MDA,SOD,ROS,GSH) 和MAPK和NF-κB的蛋白质水平被量化.
主要成果:
- 阿利治疗改善了组织病理学,并以剂量依赖的方式保护了功能.
- 氨酸显著降低了Scr,BUN,MDA的水平,以及尿路蛋白质的分泌.
- 氨酸增加了抗氧化酶活性 (SOD,GSH) 并调节了ROS/MAPK/NF-κB信号通路.
结论:
- 阿利在CKD的老鼠模型中显示出显著的脏保护作用.
- 该机制涉及通过ROS/MAPK/NF-κB通路减轻氧化应激和脂质过氧化.
- 阿利具有作为治疗脏疾病管理的治疗候选者的潜力.
更多相关视频
08:505/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
Published on: July 3, 2013
23.7K
03:13Technical Refinement of a Bilateral Renal Ischemia-Reperfusion Mouse Model for Acute Kidney Injury Research
Published on: November 3, 2023
2.3K
相关概念视频
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
40
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
40
01:25Antihypertensive Drugs: Direct Renin Inhibitors
709
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
709
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
469
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
469